Aerami Therapeutics Holdings, Inc. and FoxWayne Enterprises Acquisition Corp. Mutually Agree to Terminate Business Combination Agreement March 4, 2022 Continue Reading
Innovative Inhaled Drug Delivery Developer Aerami Therapeutics to Merge with Special Purpose Acquisition Company FoxWayne Enterprises Acquisition Corp. to Become Public Company December 7, 2021 Continue Reading
Aerami Therapeutics Appoints Barry Deutsch as Chief Financial Officer November 18, 2021 Continue Reading
Aerami Therapeutics Appoints Darlene Deptula-Hicks to its Board of Directors November 15, 2021 Continue Reading
Aerami Therapeutics Announces Orphan Drug Designation for Imatinib for the Treatment of Pulmonary Arterial Hypertension August 25, 2021 Continue Reading
Aerami Therapeutics Initiates Dosing in Phase 1 Trial of AER-901, Its Proprietary Inhaled Imatinib for the Treatment of Pulmonary Arterial Hypertension June 24, 2021 Continue Reading
Aerami Therapeutics Signs License Agreement with Hangzhou Chance Pharmaceuticals Co. Ltd. for Aerami’s PAH (pulmonary arterial hypertension) Drug Device Combination in China February 9, 2021 Continue Reading
Aerami Therapeutics to Present at the LifeSci Partners Summer Symposium July 23, 2020 Continue Reading
Aerami Therapeutics Signs a Global License Agreement with Vectura Group, Adding an Inhaled Therapy for Patients with Pulmonary Arterial Hypertension to Their Pipeline June 8, 2020 Continue Reading
Aerami Therapeutics Appoints Timm Crowder as Chief Operating Officer February 5, 2020 Continue Reading
